 |
3 Products |  |
253 Diseases | | 3 Products |
|
45 Trials |  |
1655 News |  |
| «12...10111213141516171819202122 |
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Metastases: Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 21, 2014
P2, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Metastases: Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 21, 2014
P2, N=47, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P3 trial, Metastases: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (clinicaltrials.gov) - Apr 14, 2014
P3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P2 trial, Metastases: ENCORE305: Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer (clinicaltrials.gov) - Apr 14, 2014
P2, N=180, Not yet recruiting, Sponsor: Syndax Pharmaceuticals
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Metastases: ENCORE301: Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Mar 18, 2014
P2, N=130, Completed, Sponsor: Syndax Pharmaceuticals
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy, Epigenetic controller, Metastases: MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller, Metastases: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=75, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller: MS-275 in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Metastases: Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (clinicaltrials.gov) - Feb 6, 2014
P2, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Biomarker, Trial termination, Surgery: NCI-2011-02542: Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 6, 2013
P2, N=41, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial termination, Combination therapy, Epigenetic controller, Metastases: Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 17, 2013
P1, N=44, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Terminated
- Jingzhuda (entinostat) / Syndax Pharma, EOC Pharma
Enrollment change, Combination therapy, Metastases: Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 15, 2013
P1/2, N=76, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated N=44 --> 76
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Metastases: ENCORE110: Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 8, 2013
P1, N=28, Active, not recruiting, Sponsor: Syndax Pharmaceuticals
N=44 --> 76 Recruiting --> Active, not recruiting
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P2 trial, Metastases: Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=165, Recruiting, Sponsor: National Cancer Institute (NCI)
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Metastases: Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 28, 2013
P2, N=47, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=82 --> 47
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Metastases: Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 28, 2013
P2, N=47, Completed, Sponsor: National Cancer Institute (NCI)
N=82 --> 47 Active, not recruiting --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Metastases: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (clinicaltrials.gov) - Aug 25, 2013
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=70 --> 37
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
Enrollment open, Metastases: Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (clinicaltrials.gov) - Aug 22, 2013
P2, N=120, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=70 --> 37 Not yet recruiting --> Recruiting
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
New P2 trial, Metastases: Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (clinicaltrials.gov) - Aug 20, 2013
P2, N=120, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial termination, Surgery: Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery (clinicaltrials.gov) - Jun 30, 2013
P2, N=258, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Terminated; Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of treatment after surgery.
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment open, Surgery: Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery (clinicaltrials.gov) - Jun 30, 2013
P=N/A, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of treatment after surgery. Suspended --> Recruiting
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Onureg (azacitidine oral) / BMS
New P2 trial, Metastases: Chemotherapy With or Without Epigenetic Priming in NSCLC Patients (clinicaltrials.gov) - May 2, 2013
P2, N=165, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Epigenetic controller: Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia (clinicaltrials.gov) - Apr 15, 2013
P1, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting N=46 --> 34
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial initiation date, Combination therapy: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 10, 2013
P1/2, N=50, Terminated, Sponsor: National Cancer Institute (NCI)
N=46 --> 34 Initiation date: Mar 2010 --> Oct 2010
- Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Combination therapy: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 7, 2013
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2010 --> Oct 2010 N=30 --> 24
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Combination therapy, Epigenetic controller: MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 7, 2013
P1, N=56, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 24 Completed --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 7, 2013
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Epigenetic controller: Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 2, 2012
P2, N=196, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial termination, Combination therapy: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=50, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Terminated; This study was halted prematurely by the NCI for low accrual.
- Jingzhuda (entinostat) / Syndax Pharma, EOC Pharma
Enrollment open, Combination therapy, Metastases: Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=76, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; This study was halted prematurely by the NCI for low accrual. Suspended --> Recruiting
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P1 trial, Metastases: ENCORE110: Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 7, 2012
P1, N=28, Active, not recruiting, Sponsor: Syndax Pharmaceuticals
- ||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Metastases: Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC (clinicaltrials.gov) - Apr 17, 2012
P1/2, N=132, Completed, Sponsor: Syndax Pharmaceuticals
Suspended --> Recruiting N=107 --> 132
- |||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Metastases: Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC (clinicaltrials.gov) - Apr 17, 2012
P1/2, N=132, Completed, Sponsor: Syndax Pharmaceuticals
N=107 --> 132 Active, not recruiting --> Completed
- Jingzhuda (entinostat) / Syndax Pharma, EOC Pharma
Enrollment open, Combination therapy, Epigenetic controller: A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 5, 2012
P2, N=108, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial initiation date, Metastases: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (clinicaltrials.gov) - Jan 11, 2012
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Mar 2011 --> Jan 2012
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment open, Metastases: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (clinicaltrials.gov) - Jan 11, 2012
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P1 trial, Metastases: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (clinicaltrials.gov) - Sep 12, 2011
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)